№ files_lp_4_process_3_090549
File format: docx
Character count: 2254
File size: 20 KB
A peer-reviewed research article detailing the effects of bilberry-derived anthocyanin on eye function in healthy adults after visual display terminal use, showing measurable improvements in pupillary response and accommodative function over six weeks.
Year:
2020
Region / City:
Tokyo, Japan
Subject:
Nutrition and eye health
Document Type:
Research article submission
Institution:
BGG Japan Co., Ltd.
Author:
Takahiro Sekikawa et al.
Target Audience:
Editors and researchers in functional foods
Study Duration:
6 weeks
Methodology:
Randomized, double-blind, placebo-controlled trial
Corresponding Author Email:
[email protected]
Co-authors:
Yuki Kizawa, Atsushi Takeoka, Takuji Sakiyama, Yanmei Li, Takahiro Yamada
Journal Submitted To:
Functional Foods in Health and Disease
Payment Confirmation:
Article publication fee $1095.00 US
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / city:
Global
Topic:
Academic Manuscript Submission Guidelines
Document Type:
Journal Submission Guidelines
Institution:
Not specified
Author:
Not specified
Target Audience:
Authors submitting academic papers
Effective Period:
Indefinite
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2023
Region / City:
Liege, Belgium
Field:
Anesthesia, Pharmacology
Document Type:
Clinical Trial Report
Institution:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Authors:
G Van Munster, F Beck, PY Hardy, M Carella, V Bonhomme
Target Audience:
Medical professionals, researchers in anesthesia
Period of Study:
October 21, 2021 – April 8, 2022
Approval Date:
2021
Modification Date:
N/A
Funding:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Ethics Approval:
Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège (study number 2021/190)
Clinical Trial Registration:
EudraCT: 2021-002824-19
Methodology:
Randomized, Double-blind, Placebo-controlled
Conclusion:
MS does not effectively reduce propofol requirements for hypnosis in general anesthesia during thyroidectomy
Year:
2026
Region / city:
USA, Austria, Norway, Brazil, Canada, Colombia, Denmark, UK, Australia
Subject:
Human papillomavirus vaccine, Cervical cancer prevention
Document Type:
Clinical trial report
Organization / institution:
Multiple research institutions and hospitals
Authors:
Warner K. Huh, Elmar A. Joura, Anna R. Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A. Ault, Deborah Bartholomew, Ramon M. Cestero, Edison N. Fedrizzi, Angelica L. Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T. Stapleton, Dorothy J. Wiley, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark H. Stoler, Jack Cuzick, Suzanne M. Garland, Susanne K. Kjaer, Oliver M. Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C. Roberts, Christine Shields, Alain Luxembourg
Target Audience:
Healthcare professionals, Researchers, Public health policymakers
Period of validity:
6 years
Approval date:
2026
Date of changes:
2026
Keywords:
human papillomavirus, vaccine, cervical cancer, persistent infection, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia
Funding:
Merck & Co., Inc., Kenilworth, NJ, USA
Clinical trial registration:
NCT00543543 (https://clinicaltrials.gov/ct2/show/NCT00543543
Note:
)
Word count:
4963/4500
References:
30/30
Contextual description:
This clinical trial report presents the long-term efficacy, immunogenicity, and safety outcomes of a nine-valent HPV vaccine for preventing HPV-related cervical diseases in young women.
Year:
2023
Region / City:
Multiple international locations
Topic:
Clinical trial, treatment for eosinophilic granulomatosis with polyangiitis
Document Type:
Research Article
Organization / Institution:
GlaxoSmithKline (GSK), National Institutes of Health (NIH), various academic institutions
Author:
Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, Maria C. Cid, Raashid Luqmani, Judith Brown, Stephen Mallett, Richard Philipson, Steve W. Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich
Target Audience:
Medical professionals, researchers, healthcare providers
Period of Action:
52 weeks
Approval Date:
2023-01-01
Date of Revisions:
None
Trial Title:
Eculizumab in Shiga-Toxin Producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial
Acronym:
ECUSTEC
Type of Document:
Patient Information Sheet
Study Design:
Randomised, Double-Blind, Placebo-Controlled Trial
Medical Condition:
Shiga-Toxin Producing E. Coli Haemolytic Uraemic Syndrome (STEC HUS)
Investigational Medicinal Product:
Eculizumab
Comparator:
Placebo
Target Population:
Children and Young People Aged 16–18 Years Diagnosed with STEC HUS
Sample Size:
134 Participants
Geographical Scope:
United Kingdom
Study Duration:
Four Years Recruitment with 12 Months Follow-Up per Participant
Co-ordinating Centre:
Birmingham Clinical Trials Unit (BCTU)
Intervention Schedule:
Two Doses Within One Week, First Dose Within 48 Hours of Admission
Primary Objective:
To Assess Whether Eculizumab Reduces Disease Severity in STEC HUS
Consent Requirement:
Written Informed Consent Required
Voluntary Participation:
Yes
Year:
2023
Region / City:
Fukuoka, Japan
Topic:
Medical / Health
Document Type:
Research Article
Author:
Hitomi Miyazaki, Masumi Nagae, Hiroshi Uchida, Kuniyoshi Shimizu
Target Audience:
Medical professionals, researchers
Approval Date:
December 8th, 2023
Study Participants:
18 healthy adult men and women
Ethics Approval:
Yes
Conflicts of Interest:
None
Publication Fee:
$1,595.00
Journal:
Functional Foods in Health and Disease
Co-author Contact:
Masumi Nagae, Hiroshi Uchida, Kuniyoshi Shimizu
Peer Reviewers:
Masaki Taga, Hiroaki Masuzaki, Toshio Hosaka, Mei Hui Liu, Anne Nilsson
Study ID:
A211801
Study name:
BRCA-P
Document type:
Clinical trial eligibility criteria summary
Study type:
Randomized, double-blind, placebo-controlled clinical trial
Phase:
Phase 3
Geographic scope:
International multi-center study
Medical field:
Oncology
Target condition:
Breast cancer prevention in BRCA1 germline mutation carriers
Investigational drug:
Denosumab
Control:
Placebo
Population:
Women with confirmed deleterious or likely deleterious BRCA1 germline mutation aged 25–55 years
Key inclusion criteria:
No evidence of breast cancer by MRI or mammography and clinical breast examination within 6 months, no clinical evidence of ovarian cancer, ECOG performance status 0–1, written informed consent
Key exclusion criteria:
Prior bilateral mastectomy, history of breast or ovarian cancer, prior denosumab use, pregnancy or lactation, clinically relevant hypocalcaemia, certain prior hormonal or investigational treatments, significant medical or psychiatric conditions, active hepatitis B, hepatitis C, or HIV infection
Study duration:
12 weeks
Location:
South Carolina, United States
Clinical site:
Prisma Health IBD Clinic
Participating institution:
University of South Carolina
Medical specialty:
Gastroenterology
Disease focus:
Ulcerative colitis
Intervention:
American Ginseng
Study design:
Double-blind placebo-controlled clinical trial
Planned sample size:
80 participants
Lead clinical collaborator:
Dr. Joseph Meserve
Participant population:
Adults aged 18 years and older with confirmed ulcerative colitis on stable 5-ASA therapy
Primary recruitment source:
Prisma Health Gastroenterology and Hepatology patient database
Recruitment coordination:
USC research team and Prisma Health staff
Inclusion criteria:
Confirmed ulcerative colitis diagnosis, UCDAI score greater than 3, stable 5-ASA therapy, informed consent
Exclusion criteria:
Crohn’s disease or other IBD conditions, biologic or small molecule immunotherapy use, pregnancy or breastfeeding, active infection, active malignancy, investigational drug participation, ginseng allergy, medications causing interaction risks
Participant compensation:
Up to $200 via Visa gift cards
Data collection:
Blood, stool, and urine samples
Recruitment methods:
Patient database identification, physician referrals, brochures and flyers, clinic outreach, online announcements
Retention measures:
Participant education, regular communication, flexible scheduling, incentives, community engagement
Year:
2023
Region / City:
Liege, Belgium
Field:
Anesthesia, Pharmacology
Document Type:
Clinical Trial Report
Institution:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Authors:
G Van Munster, F Beck, PY Hardy, M Carella, V Bonhomme
Target Audience:
Medical professionals, researchers in anesthesia
Period of Study:
October 21, 2021 – April 8, 2022
Approval Date:
2021
Modification Date:
N/A
Funding:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Ethics Approval:
Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège (study number 2021/190)
Clinical Trial Registration:
EudraCT: 2021-002824-19
Methodology:
Randomized, Double-blind, Placebo-controlled
Conclusion:
MS does not effectively reduce propofol requirements for hypnosis in general anesthesia during thyroidectomy
Year:
2023
Region / City:
Multiple international locations
Topic:
Clinical trial, treatment for eosinophilic granulomatosis with polyangiitis
Document Type:
Research Article
Organization / Institution:
GlaxoSmithKline (GSK), National Institutes of Health (NIH), various academic institutions
Author:
Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, Maria C. Cid, Raashid Luqmani, Judith Brown, Stephen Mallett, Richard Philipson, Steve W. Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich
Target Audience:
Medical professionals, researchers, healthcare providers
Period of Action:
52 weeks
Approval Date:
2023-01-01
Date of Revisions:
None
Trial Title:
Eculizumab in Shiga-Toxin Producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial
Acronym:
ECUSTEC
Type of Document:
Patient Information Sheet
Study Design:
Randomised, Double-Blind, Placebo-Controlled Trial
Medical Condition:
Shiga-Toxin Producing E. Coli Haemolytic Uraemic Syndrome (STEC HUS)
Investigational Medicinal Product:
Eculizumab
Comparator:
Placebo
Target Population:
Children and Young People Aged 16–18 Years Diagnosed with STEC HUS
Sample Size:
134 Participants
Geographical Scope:
United Kingdom
Study Duration:
Four Years Recruitment with 12 Months Follow-Up per Participant
Co-ordinating Centre:
Birmingham Clinical Trials Unit (BCTU)
Intervention Schedule:
Two Doses Within One Week, First Dose Within 48 Hours of Admission
Primary Objective:
To Assess Whether Eculizumab Reduces Disease Severity in STEC HUS
Consent Requirement:
Written Informed Consent Required
Voluntary Participation:
Yes
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Year:
2022
Region / City:
Yokohama, Kanagawa, Japan
Subject:
Postprandial blood glucose regulation
Document Type:
Research article submission
Organization / Institution:
MAINICHIEGAO.CO.,LTD.
Authors:
Junyoo Takizawa, Asami Baba, Tsuyoshi Takara
Target Audience:
Editors of Functional Foods in Health and Disease
Study Period:
Not explicitly stated
Date of Submission:
December 24, 2022
Funding / Publication Fee:
$1,295.00 USD, bank transfer
Recommended Peer Reviewers:
Dr. Abolghassem Djazayery, Dr. Mark Lown, Dr. Oran Kwon, Dr. Kristine Færch, Dr. Wen Xin Janice Lim
Methodology:
Randomized, placebo-controlled, crossover clinical trials
Participants:
Healthy Japanese men and women
Intervention:
“PAKU-PAKU KOUBO-KUN” containing yeast and mulberry extract
Outcome Measures:
Postprandial blood glucose incremental area under the curve
Year:
2023
Authors:
Junyoo Takizawa, Asami Baba, Tsuyoshi Takara
Correspondence:
Junyoo Takizawa, [email protected]
Institution:
MAINICHIEGAO.CO.,LTD., Yokohama, Kanagawa, Japan
Type of document:
Research article submission
Target journal:
Functional Foods in Health and Disease
Subject:
Postprandial glycemic control, dietary supplement, yeast, mulberry extract
Study type:
Randomized, placebo-controlled, crossover clinical trial
Population:
Healthy Japanese adults
Date of submission:
February 27, 2023
Funding:
Author-funded (publication fee $1,295 USD)
Peer reviewers suggested:
Dr. Abolghassem Djazayery, Dr. Mark Lown, Dr. Oran Kwon, Dr. Kristine Færch, Dr. Wen Xin Janice Lim
Study ID:
A211801
Study name:
BRCA-P
Document type:
Clinical trial eligibility criteria summary
Study type:
Randomized, double-blind, placebo-controlled clinical trial
Phase:
Phase 3
Geographic scope:
International multi-center study
Medical field:
Oncology
Target condition:
Breast cancer prevention in BRCA1 germline mutation carriers
Investigational drug:
Denosumab
Control:
Placebo
Population:
Women with confirmed deleterious or likely deleterious BRCA1 germline mutation aged 25–55 years
Key inclusion criteria:
No evidence of breast cancer by MRI or mammography and clinical breast examination within 6 months, no clinical evidence of ovarian cancer, ECOG performance status 0–1, written informed consent
Key exclusion criteria:
Prior bilateral mastectomy, history of breast or ovarian cancer, prior denosumab use, pregnancy or lactation, clinically relevant hypocalcaemia, certain prior hormonal or investigational treatments, significant medical or psychiatric conditions, active hepatitis B, hepatitis C, or HIV infection
Study duration:
12 weeks
Location:
South Carolina, United States
Clinical site:
Prisma Health IBD Clinic
Participating institution:
University of South Carolina
Medical specialty:
Gastroenterology
Disease focus:
Ulcerative colitis
Intervention:
American Ginseng
Study design:
Double-blind placebo-controlled clinical trial
Planned sample size:
80 participants
Lead clinical collaborator:
Dr. Joseph Meserve
Participant population:
Adults aged 18 years and older with confirmed ulcerative colitis on stable 5-ASA therapy
Primary recruitment source:
Prisma Health Gastroenterology and Hepatology patient database
Recruitment coordination:
USC research team and Prisma Health staff
Inclusion criteria:
Confirmed ulcerative colitis diagnosis, UCDAI score greater than 3, stable 5-ASA therapy, informed consent
Exclusion criteria:
Crohn’s disease or other IBD conditions, biologic or small molecule immunotherapy use, pregnancy or breastfeeding, active infection, active malignancy, investigational drug participation, ginseng allergy, medications causing interaction risks
Participant compensation:
Up to $200 via Visa gift cards
Data collection:
Blood, stool, and urine samples
Recruitment methods:
Patient database identification, physician referrals, brochures and flyers, clinic outreach, online announcements
Retention measures:
Participant education, regular communication, flexible scheduling, incentives, community engagement